4 November 2024
Nuformix
plc
("Nuformix" or the "Company")
Result of General
Meeting
Nuformix plc (LSE:NFX), a
pharmaceutical development company targeting unmet medical needs in
fibrosis and oncology via drug repurposing,
announces that at the General Meeting of the Company held earlier
today all resolutions put to shareholders were duly passed and
approved by way of a show of hands. The proxies received
ahead of the General Meeting, are reported below:
|
|
Resolution
|
Ordinary/ Special
|
For
|
|
Against
|
|
Total votes cast
|
|
|
|
|
No. of votes
|
%
|
No. of votes
|
%
|
|
|
1
|
Subdivision of the ordinary
shares
|
Ordinary
|
164,225,020
|
98.00%
|
3,356,013
|
2.00%
|
167,581,033
|
|
2
|
To authorise the directors to allot
shares
|
Ordinary
|
163,856,186
|
97.99%
|
3,361,741
|
2.01%
|
167,217,927
|
|
3
|
To authorise the directors to
disapply pre-emption rights
|
Special
|
163,856,186
|
98.04%
|
3,273,557
|
1.96%
|
167,129,743
|
|
4
|
Amendment of the Company's Articles
of Association
|
Special
|
163,856,186
|
98.04%
|
3,273,557
|
1.96%
|
167,129,743
|
A vote withheld is not a vote in law
and is not counted in the calculation of votes validly cast for or
against a resolution.
Full details of the Resolutions are
contained in the Notice of General Meeting which is available,
appended to the Prospectus, on the Company's website at:
https://nuformix.com/document-center/
Following the passing of the
Resolutions at the General Meeting, the expected timetable of
events remains the same as documented in the Prospectus and is as
follows:
|
|
2024
|
|
Record Date for the Capital
Reorganisation
|
6.00 p.m.
on 4 November
|
|
Admission of New Ordinary Shares
effective and commencement of dealing
|
8.00 a.m.
on 5 November
|
|
Expected date for CREST accounts to
be credited
|
5
November
|
|
Despatch of definitive certificates
(where applicable) expected by no later than
|
11
November
|
Admission and Total Voting Rights
An application has been made to the
London Stock Exchange for the 600,000,000
New Ordinary Shares, to be issued pursuant to the conditional £300,000 fundraise announced on 20 September
2024, to be admitted to the equity shares (transition)
category of the Financial Conduct Authority's Official List and to
trading on the Main Market of the London Stock Exchange
("Admission"). It is expected that Admission
and unconditional dealings in the New Ordinary
Shares will commence on the London Stock Exchange at 8.00 a.m. on 5
November 2024.
Following Admission of the New
Ordinary Shares, the total number of Ordinary Shares in issue will
be 1,419,309,368, each with one voting right. The Company
does not hold any rights in treasury. The total voting rights
figure is therefore 1,419,309,368 and can be used by shareholders
as the denominator for the calculations by which they will
determine whether they are required to notify their interest in, or
a change of their interest in, the Company under the Disclosure
Guidance and Transparency Rules of the Financial Conduct
Authority.
Terms used in this announcement
shall, unless the context otherwise requires, be as defined in the
Prospectus published by the Company on 16 October 2024.
Enquiries:
|
Nuformix plc
|
|
|
Dr Dan Gooding, Executive
Director
|
Via IFC Advisory
|
|
CMC
Markets
|
|
|
Douglas Crippen
|
+44 (0) 20 3003 8632
|
|
|
|
|
IFC
Advisory Limited
|
|
|
Tim Metcalfe
Zach Cohen
|
+44 (0) 20 3934 6630
nuformix@investor-focus.co.uk
|
About Nuformix
Nuformix is a pharmaceutical
development company targeting unmet medical needs in fibrosis and
oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug
forms, with improved physical properties, to develop new products
in new indications that are, importantly, differentiated from the
original (by way of dosage, delivery route or presentation), thus
creating new and attractive commercial opportunities.
Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.